

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

Cost-comparison [Somapacitan for treating growth hormone deficiency in children and young people – ID6178]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

It was noted during the consultation that growth hormone deficiency disproportionately impacts boys. Additionally, it was noted that socioeconomic status negatively impacts on adherence to therapy.

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

Issues related to differences in prevalence or incidence of a disease cannot typically be addressed in a technology appraisal. However, the committee will consider whether its recommendations could have a different impact on people protected by the equality legislation than on the wider population.

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No changes have been made

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No

Approved by Associate Director (name): Richard Diaz

Date: 23 May 2023